Loading stock data…
NTRA
$207.28+1.12 (+0.54%)
Market ClosedLast close May 1
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Natera, Inc. in the Healthcare sector is trading at $207.28. The stock is currently 19% below its 52-week high of $256.36, remaining 5.3% above its 200-day moving average. Technical signals show neutral RSI of 53 and bullish MACD crossover, explaining why NTRA maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 53) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$207.28
Potential Upside
5%
Whystock Fair Value$217.64
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus18 analysts
Mean target$258.00+24.5%
Range$190.00 – $300.00
Fundamentals
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of tre...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$29.45B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.68
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-14.79%
Volume
Today's trading volume
946,666
Recent News
William Blair Initiates Natera (NTRA) With Outperform
Natera, Inc. (NASDAQ:NTRA) is one of the Stocks that Billionaire Druckenmiller and Jim Cramer like. William Blair initiated coverage of Natera, Inc. (NASDAQ:NTRA) with an Outperform rating on the company’s stock on April 14, 2026. The firm recommends the stock as a core, long-term growth holding. William Blair highlights Natera, Inc. (NASDAQ:NTRA)’s leadership in major […]
Extreme Networks And 2 Additional Stocks Estimated To Be Trading Below Their Fair Value
In the last week, the United States market has stayed flat, yet it is up 29% over the past year with earnings forecasted to grow by 16% annually. In such a climate, identifying stocks that are potentially undervalued can present opportunities for investors looking to capitalize on discrepancies between stock prices and their intrinsic values.
Alignment Healthcare (ALHC) Q1 Earnings and Revenues Top Estimates
Alignment Healthcare (ALHC) delivered earnings and revenue surprises of +400.00% and +1.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Exploring High Growth US Tech Stocks This April 2026
The United States market has shown impressive growth, with a 28% increase over the past year despite remaining flat last week, and earnings are projected to grow by 16% annually. In this context, identifying high-growth tech stocks involves focusing on companies that demonstrate strong innovation and adaptability in an evolving economic landscape.
Should You Be Bullish on Natera (NTRA)?
Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. Baron Health Care Fund (the Fund) declined 6.97% (Institutional Shares) in the quarter, compared to the 4.88% decline for the Russell 3000 Health Care Index (the Benchmark) and […]